BioVersys AG (XSWX:BIOV) PS Ratio: 197.08 (As of Jul. 05, 2026)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG PS Ratio?

BioVersys AG XSWX:BIOV 4 PS Ratio is 197.08 as of Jul. 05, 2026. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 931 Biotechnology companies, BioVersys AG ranks worse than 89.26% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioVersys AG's share price is CHF27.00. BioVersys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.14. Hence, BioVersys AG's PS Ratio for today is 197.08.

The historical rank and industry rank for BioVersys AG's PS Ratio or its related term are showing as below:

XSWX:BIOV' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 197.08
Current: 197.08

During the past 2 years, BioVersys AG's highest PS Ratio was 197.08. The lowest was 0.00. And the median was 0.00.

XSWX:BIOV's PS Ratio is ranked worse than
89.26% of 931 companies
in the Biotechnology industry
Industry Median: 9.93 vs XSWX:BIOV: 197.08

BioVersys AG's Revenue per Sharefor the six months ended in Dec. 2025 was CHF0.14. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.14.

Back to Basics: PS Ratio


BioVersys AG  (XSWX:BIOV) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BioVersys AG PS Ratio Related Terms


BioVersys AG PS Ratio Historical Data

* Premium members only.

The historical data trend for BioVersys AG's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG PS Ratio Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
PS Ratio
0.00 171.83

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
PS Ratio 0.00 0.00 0.00 0.00

XSWX:BIOV vs VRTX, REGN, ALNY: PS Ratio Comparison

For the Biotechnology subindustry, BioVersys AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVersys AG PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's PS Ratio distribution charts can be found below:

* The bar in red indicates where BioVersys AG's PS Ratio falls into.


XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BioVersys AG's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=27.00/0.137
=197.08

BioVersys AG's Share Price of today is CHF27.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioVersys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 197.08 mean?
BioVersys AG (XSWX:BIOV) has a PS Ratio of 197.08 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #831 out of 931 companies in the Biotechnology industry, placing it in the top 89.3%.
Is BioVersys AG's PS Ratio too high?
BioVersys AG's current PS Ratio is 197.08. The Biotechnology industry median PS Ratio is 9.93. BioVersys AG's value of 197.08 is 1884.7% above this industry median. Based on the distribution chart, BioVersys AG ranks #831 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #831 out of 931 companies for PS Ratio. This places BioVersys AG in the lower half of its industry. The industry median PS Ratio is 9.93. BioVersys AG's value of 197.08 is 1884.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVersys AG's current PS Ratio of 197.08 is 1884.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current PS Ratio is 197.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current PS Ratio of 197.08. The current PS Ratio is 197.08 and 1884.7% above the Biotechnology industry median of 9.93. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current PS Ratio is 197.08 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price